Is Anticancer Drug Development Heading in the Right Direction?

被引：134

作者：

Hambley, Trevor W. ^{[1
]}

机构：

[1] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia

来源：

CANCER RESEARCH | 2009年 / 69卷 / 04期

关键词：

SOLID TUMORS; CANCER; CHEMOTHERAPY; PENETRATION; PATHWAYS; DESIGN;

D O I：

10.1158/0008-5472.CAN-08-3786

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The success of molecularly targeted agents, such as imatinib, has led to expectations of a new era in anticancer drug development, and to a greatly increased focus on targeting as a strategy. However, the number of successes to date is small, and recent results suggest that the success of imatinib, for instance, in treating chronic myelogenous leukemia and gastrointestinal stromal tumor may be the exception rather than the rule. Here, we argue that the search for new anticancer agents needs to continue on as many fronts as possible, and not be focused on one strategy alone. [Cancer Res 2009:69(4):1259-62]

引用

页码：1259 / 1261

页数：3

共 19 条

[1] 'Clean' or 'dirty' - Just how selective do drugs need to be? [J].

Abbenante, Giovanni ;

Reid, Robert C. ;

Fairlie, David P. .

AUSTRALIAN JOURNAL OF CHEMISTRY, 2008, 61 (09) :654-660

[2] Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].

Chin, L. ;

Meyerson, M. ;

Aldape, K. ;

Bigner, D. ;

Mikkelsen, T. ;

VandenBerg, S. ;

Kahn, A. ;

Penny, R. ;

Ferguson, M. L. ;

Gerhard, D. S. ;

Getz, G. ;

Brennan, C. ;

Taylor, B. S. ;

Winckler, W. ;

Park, P. ;

Ladanyi, M. ;

Hoadley, K. A. ;

Verhaak, R. G. W. ;

Hayes, D. N. ;

Spellman, Paul T. ;

Absher, D. ;

Weir, B. A. ;

Ding, L. ;

Wheeler, D. ;

Lawrence, M. S. ;

Cibulskis, K. ;

Mardis, E. ;

Zhang, Jinghui ;

Wilson, R. K. ;

Donehower, L. ;

Wheeler, D. A. ;

Purdom, E. ;

Wallis, J. ;

Laird, P. W. ;

Herman, J. G. ;

Schuebel, K. E. ;

Weisenberger, D. J. ;

Baylin, S. B. ;

Schultz, N. ;

Yao, Jun ;

Wiedemeyer, R. ;

Weinstein, J. ;

Sander, C. ;

Gibbs, R. A. ;

Gray, J. ;

Kucherlapati, R. ;

Lander, E. S. ;

Myers, R. M. ;

Perou, C. M. ;

McLendon, Roger .

NATURE, 2008, 455 (7216) :1061-1068

[3] New approaches to molecular cancer therapeutics [J].

Collins, Ian ;

Workman, Paul .

NATURE CHEMICAL BIOLOGY, 2006, 2 (12) :689-700

[4] The design of drugs that target tumour hypoxia [J].

Denny, WA .

AUSTRALIAN JOURNAL OF CHEMISTRY, 2004, 57 (09) :821-828

[5] Studies of a cobalt(III) complex of the MMP inhibitor marimastat: A potential hypoxia-activated prodrug [J].

Failes, Timothy W. ;

Cullinane, Carleen ;

Diakos, Connie I. ;

Yamamoto, Natsuho ;

Lyons, J. Guy ;

Hambley, Trevor W. .

CHEMISTRY-A EUROPEAN JOURNAL, 2007, 13 (10) :2974-2982

[6] Engineering tumors with 3D scaffolds [J].

Fischbach, Claudia ;

Chen, Ruth ;

Matsumoto, Takuya ;

Schmelzle, Tobias ;

Brugge, Joan S. ;

Polverini, Peter J. ;

Mooney, David J. .

NATURE METHODS, 2007, 4 (10) :855-860

[7] Basis for design and development of Platinum(IV) anticancer complexes [J].

Hall, Matthew D. ;

Mellor, Howard R. ;

Callaghan, Richard ;

Hambley, Trevor W. .

JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (15) :3403-3411

[8] Physiological targeting to improve anticancer drug selectivity [J].

Hambley, Trevor W. .

AUSTRALIAN JOURNAL OF CHEMISTRY, 2008, 61 (09) :647-653

[9] Cancer complexity slows quest for cure [J].

Hayden, Erika Check .

NATURE, 2008, 455 (7210) :148-148

[10] Stressed out hearts [J].

Hutchinson, Ezzie .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :720-720

← 1 2 →